185 related articles for article (PubMed ID: 31989379)
1. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
de Boniface J; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Olofsson Bagge R; Rydén L; Sund M;
Breast Cancer Res Treat; 2020 Feb; 180(1):167-176. PubMed ID: 31989379
[TBL] [Abstract][Full Text] [Related]
2. Do clinical trials truly mirror their target population? An external validity analysis of national register versus trial data from the Swedish prospective SENOMIC trial on sentinel node micrometastases in breast cancer.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Breast Cancer Res Treat; 2019 Sep; 177(2):469-475. PubMed ID: 31236811
[TBL] [Abstract][Full Text] [Related]
3. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
de Boniface J; Frisell J; Andersson Y; Bergkvist L; Ahlgren J; Rydén L; Olofsson Bagge R; Sund M; Johansson H; Lundstedt D;
BMC Cancer; 2017 May; 17(1):379. PubMed ID: 28549453
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
Appelgren M; Sackey H; Wengström Y; Johansson K; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Rydén L; Sund M; Alkner S; Vrou Offersen B; Filtenborg Tvedskov T; Christiansen P; de Boniface J;
Breast; 2022 Jun; 63():16-23. PubMed ID: 35279508
[TBL] [Abstract][Full Text] [Related]
5. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
[TBL] [Abstract][Full Text] [Related]
6. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
[TBL] [Abstract][Full Text] [Related]
7. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
8. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.
Henke G; Knauer M; Ribi K; Hayoz S; Gérard MA; Ruhstaller T; Zwahlen DR; Muenst S; Ackerknecht M; Hawle H; Fitzal F; Gnant M; Mátrai Z; Ballardini B; Gyr A; Kurzeder C; Weber WP
Trials; 2018 Dec; 19(1):667. PubMed ID: 30514362
[TBL] [Abstract][Full Text] [Related]
9. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V; Cole BF; Viale G; Veronesi P; Vicini E; Intra M; Mazzarol G; Massarut S; Zgajnar J; Taffurelli M; Littlejohn D; Knauer M; Tondini C; Di Leo A; Colleoni M; Regan MM; Coates AS; Gelber RD; Goldhirsch A;
Lancet Oncol; 2018 Oct; 19(10):1385-1393. PubMed ID: 30196031
[TBL] [Abstract][Full Text] [Related]
10. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
11. Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer.
Zetterlund LH; Frisell J; Zouzos A; Axelsson R; Hatschek T; de Boniface J; Celebioglu F
Breast Cancer Res Treat; 2017 May; 163(1):103-110. PubMed ID: 28224384
[TBL] [Abstract][Full Text] [Related]
12. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
[TBL] [Abstract][Full Text] [Related]
13. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
14. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of application of Z0011 derived criteria to omit axillary lymph node dissection in node positive breast cancer patients.
Verheuvel NC; Voogd AC; Tjan-Heijnen VC; Roumen RM
Eur J Surg Oncol; 2016 Aug; 42(8):1162-8. PubMed ID: 27265036
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study.
Hennigs A; Riedel F; Feißt M; Köpke M; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Heil J
Ann Surg Oncol; 2019 Aug; 26(8):2435-2443. PubMed ID: 31049766
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative palpation of sentinel lymph nodes can accurately predict axilla in early breast cancer.
Ozkurt E; Yardımcı E; Tükenmez M; Ersoy YE; Yilmaz R; Cabioğlu N; Karanlık H; Kulle CB; Malya FU; Önder S; Gucin Z; İğci A; Özmen V; Dinççağ AS; Müslümanoğlu M
Breast J; 2019 Jan; 25(1):96-102. PubMed ID: 30419607
[TBL] [Abstract][Full Text] [Related]
18. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node.
Houvenaeghel G; Cohen M; Raro P; De Troyer J; de Lara CT; Gimbergues P; Gauthier T; Faure-Virelizier C; Vaini-Cowen V; Lantheaume S; Regis C; Darai E; Ceccato V; D'Halluin G; Del Piano F; Villet R; Jouve E; Beedassy B; Theret P; Gabelle P; Zinzindohoue C; Opinel P; Marsollier-Ferrer C; Dhainaut-Speyer C; Colombo PE; Lambaudie E; Tallet A; Boher JM;
BMC Cancer; 2018 Nov; 18(1):1153. PubMed ID: 30463611
[TBL] [Abstract][Full Text] [Related]
19. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
[TBL] [Abstract][Full Text] [Related]
20. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
